ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
31633 results sorted by trial registration date.
Clear all

  • Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

    To compare the efficacy of pegilodecakin in combination with FOLFOX versus FOLFOX alone in participants with metastatic pancreatic cancer as measured by overall survival.

    Registration number:
    NCT02923921
    Broad health category:
    • Pancreatic Cancer
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease

    The purpose of this study is to assess the safety, tolerability and efficacy of two infusions of CYP-001 in adults with steroid-resistant GvHD.

    Registration number:
    NCT02923375
    Broad health category:
    • Graft vs Host Disease
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • SA
    • Not specified
    Gender:
    • All

  • Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

    This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.

    Registration number:
    NCT02922036
    Broad health category:
    • Heart Failure
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • NSW
    • QLD
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

    The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.

    Registration number:
    NCT02920697
    Broad health category:
    • Chronic Lymphocytic Leukaemia (CLL)
    • B-Cell Non-Hodgkin Lymphoma (NHL)
    • Multiple Myeloma (MM)
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

    The purpose of this study is to determine the safety profile and tolerability of S 055746 in patients with AML, and high or very high risk MDS, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.

    Registration number:
    NCT02920541
    Broad health category:
    • Acute Myeloid Leukaemia (AML)
    • Myelodysplastic Syndrome (MDS)
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • Improving Partnerships With Family Members of ICU Patients

    The purpose of this study is to improve the outcomes of critically ill older patients and the health outcomes of their families by capacitating and partnering with families in optimizing patient/family centered care.

    Registration number:
    NCT02920086
    Broad health category:
    • Critical Illness
    Specific health category:
    • Not specified
    Trial focus:
    • Other
    Recruitment status:
    • UNKNOWN
    Recruitment sites:
    • QLD
    • Not specified
    Gender:
    • All

  • The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health

    The investigators hypothesise that carnosine supplementation will improve: 1. glycaemic control 2. cardiovascular risk factors 3. cognitive outcomes in patients with prediabetes and type 2 diabetes, and this will be modulated by reduction in chronic low grade inflammation, oxidative stress and circulating advanced glycation end products levels. 3. Aims To determine the potential of carnosine supplementation for 14 weeks to improve glycaemic control in type 2 diabetes, reduce risk factors for cardiovascular disease and improve cognitive function as well as identify metabolic pathways involved, specifically by: 1. Improving glycaemic control (HBA1c, fasting and 2 hour glucose and glucose area under the curve after oral glucose tolerance test) 2. Reducing cardiovascular risk factors (lipids; arterial (aortic) stiffness; central blood pressure (cBP); endothelial function). 3. Improve cognitive function (global cognitive score formed by a composite of 4 cognitive tests) 4. Decrease the chronic low grade inflammation, oxidative stress, advanced glycation end products, and advanced lipoxidation end products, and increase detoxification of reactive carbonyl species (RCSs).

    Registration number:
    NCT02917928
    Broad health category:
    • Poor Glycemic Control
    • Cardiovascular Risk Factors
    • Cognitive Function 1, Social
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • UNKNOWN
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).

    Registration number:
    NCT02915744
    Broad health category:
    • Metastasis
    • Breast Cancer
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • WA
    • Not specified
    Gender:
    • All

  • Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH

    The primary objective of this study is to evaluate the effect of KRN23 (burosumab) therapy in improving rickets in children with XLH compared with active control (oral phosphate/active vitamin D).

    Registration number:
    NCT02915705
    Broad health category:
    • X-Linked Hypophosphatemia
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • NSW
    • Not specified
    Gender:
    • All

  • A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

    The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.

    Registration number:
    NCT02915159
    Broad health category:
    • Sjogrens Disease
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Completed
    Recruitment sites:
    • QLD
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials